Pasini B, Hofstra R M, Yin L, Bocciardi R, Santamaria G, Grootscholten P M, Ceccherini I, Patrone G, Priolo M, Buys C H
Laboratorio di Genetica Molecolare, Istituto Giannina Gaslini Largo G. Gaslini 5, Genova Quarto, Italy.
Oncogene. 1995 Nov 2;11(9):1737-43.
The RET proto-oncogene, a transmembrane tyrosine kinase receptor, is involved in the development of at least five different disease phenotypes. RET is activated through somatic rearrangements in a number of cases of papillary thyroid carcinoma while germ-line point mutations are associated with three inherited cancer syndromes MEN 2A, MEN 2B and FMTC. Moreover, point mutations or heterozygous deletions of RET are found in the dominant form of Hirschsprung disease or congenital colonic aganglionosis. We cloned the entire RET genomic sequence in a contig of cosmids encompassing 150 kb, from the CA repeat sTCL-2 to the region upstream the RET promoter, and established the position of the 20 exons of the RET gene with respect to a detailed restriction map based on eight endonucleases. A new highly polymorphic CA repeat sequence was identified within intron 5 of RET (RET-INT5). Finally the orientation of RET on chromosome 10q11.2 made it possible to orientate three other genes rearranged with RET in papillary thyroid carcinomas, namely H4/D10S170 on 10q21, R1 alpha on 17q23 and RFG2/Ele1 on 10q11.2.
RET原癌基因是一种跨膜酪氨酸激酶受体,至少与五种不同的疾病表型的发生发展有关。在许多乳头状甲状腺癌病例中,RET通过体细胞重排被激活,而种系点突变与三种遗传性癌症综合征相关,即2A型多发性内分泌腺瘤病(MEN 2A)、2B型多发性内分泌腺瘤病(MEN 2B)和家族性甲状腺髓样癌(FMTC)。此外,在先天性巨结肠或先天性结肠无神经节症的显性形式中发现了RET的点突变或杂合缺失。我们从CA重复序列sTCL - 2到RET启动子上游区域,在一个包含150 kb的黏粒重叠群中克隆了整个RET基因组序列,并根据八种核酸内切酶建立了RET基因20个外显子相对于详细限制酶切图谱的位置。在RET的内含子5(RET - INT5)中鉴定出一个新的高度多态性的CA重复序列。最后,RET在染色体10q11.2上的方向使得确定在乳头状甲状腺癌中与RET重排的其他三个基因的方向成为可能,这三个基因分别是位于10q21的H4/D10S170、位于17q23的R1α和位于10q11.2的RFG2/Ele1。